New Delhi [India], November 19 (ANI): Major drug marker Serum of Institute of India (SII) on Thursday said that the coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years
New Delhi [India], November 12 (ANI): The Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) have announced the completion of enrolment of phase 3 clinical trials for COVISHIELD in India.
Pune (Maharashtra) [India], September 29 (ANI): Serum Institute of India (SII) will produce up to an additional 100 million COVID-19 vaccine doses for India and low and middle-income countries (LMICs) in 2021.
Pune (Maharashtra) [India], September 19 (ANI): Serum Institute of India (SII) is all set to begin phase three trials of the Covishield Vaccine developed by AstraZeneca and Oxford University at Sassoon General Hospital in Pune, the hospital administration said on Saturday.
New Delhi [India], September 16 (ANI): The Drugs Controller General of India (DCGI) has allowed Serum Institute of India (SII) to restart its phase two and three clinical trials for COVID-19 vaccine after the pharma major submitted the recommendations of the Data Safety Monitoring Board (DSM
New Delhi [India], September 12 (ANI): Hours after clinical trials for AstraZeneca and Oxford University coronavirus vaccine resumed on Saturday in the UK, pharma major Serum Institute of India (SII) said it will resume the trials in India once Drugs Controller General of India (DCGI) gives
New Delhi [India], September 12 (ANI): The Drugs Controller General of India (DCGI) Dr VG Somani on Friday ordered the pharma giant Serum Institute of India (SII) to suspend any new recruitment in phase 2 and 3 clinical trials for COVID-19 vaccine till further orders.
New Delhi [India], September 9 (ANI): Hours after the Drugs Controller General of India (DCGI) issued a show-cause notice Serum Institute of India (SII) asking for an explanation as to why the ongoing clinical trial of Covishield vaccine candidate has not been suspended till doubts about
New Delhi [India], September 9 (ANI): The Drugs Regulator General of India (DCGI) has issued a show-cause notice to pharma giant Serum Institute of India (SII) asking for an explanation as to why the ongoing clinical trial of Covishield vaccine candidate has not been suspended till doubts
New Delhi [India], September 9 (ANI): After AstraZeneca suspended the trials of COVID-19 vaccine in the UK, Indian pharmaceutical giant Serum Institue of India (SII) on Wednesday clarified that testing of the possible vaccine candidate in India is ongoing and has not faced any issue so far.
Pune (Maharashtra) [India], Aug 23 (ANI): The current claims over the Coronavirus vaccine, Covishield, are completely false and it will be commercialised when trials prove successful and regulatory approvals are in place, said Serum Institute of India (SII) on Sunday.
Moscow [Russia], August 11 (ANI): After the first coronavirus vaccine in the world was registered in Russia, Russian Direct Investment Fund (RDIF) CEO Kirill Dmitriev said, in his opinion piece for Sputnik, that the secret behind the high speed of Russia's COVID-19 vaccine creation was the c